The UK and US have agreed to a major trade agreement that will ensure no levies on UK pharmaceutical shipments entering the American market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has committed to raise expenditure on medicines through the public health system. This pledge secures that tariffs on these vital products will remain at nothing for a timeframe of three years.
This development follows previous threats to hike duties on patented pharmaceutical imports, with figures mentioned as high as double the cost.
"This agreement with the United Kingdom strengthens the global environment for new treatments and establishes much-needed fairness to U.S.–U.K. medicine commerce," an announcement noted.
Commercial Impact
Drugs represent one of the the United Kingdom's biggest goods shipped to the US, which is clearly the biggest market for major British pharmaceutical firms.
Statistics reveal that in the year to the end of September, the UK exported drugs worth £11.1bn to the US. This figure represented nearly one-fifth of all goods exports in that period.
"This guarantee secures employment, boosts funding and sets the stage for the UK to emerge as a worldwide center for life sciences," a minister commented.
Specific NHS Changes
The deal includes several key changes from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it considers new treatments to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a aim to increase overall NHS spending on treatments from 0.3 percent of Gross Domestic Product to 0.6% over the next decade.
- Payback Limit: The percentage drug companies must refund to the NHS to prevent overspending will be restricted at 15%. Previously, refunds were more than twenty percent.
Recent Tensions
This agreement takes place against a long-running dispute between the drug companies and the British authorities over spending levels and NHS adoption.
These tensions were exacerbated by assertions that US consumers were charged several times more for the same drugs than people in the Britain and the EU.
Recently, several significant manufacturing plans in the UK have been halted or cancelled, while substantial investments have been pledged toward US facilities.
The Science Minister stated that the NHS had to spend more on medicines, noting that its budget allocation on drugs had declined as a proportion of its overall budget over the last ten years.
